



Centre for Probe Development  
and Commercialization

*Nuclear Medicine for All  
Canadians*



# CPDC History

**Radiopharma  
Leadership Since  
2008**

**17 years of radiopharmaceutical focus and success**

---

**Unique understanding of radiopharmaceutical market  
needs and future opportunities**

---

**Experience in radiopharma product development,  
company creation, in-licensing, out-licensing**

---

**Expansive network and relationships across Canada, the  
US and internationally**

---

**Dedicated and experienced team and Board based in  
Hamilton**

## Experienced leadership

---

# Senior CPDC Team

**Owen Roberts, CFA, CEO**

More than 25 years focused on biotech drug discovery and development, including advancing multiple products through Phase 2

**Catherine Love, MSc, CFA, VP, Business Development & Investments**

More than 20 years focused on life science investing across seed-stage to public multinationals, VC & drug royalty investing, and building not-for-profits

**Oscar Grilli, BSc, PEng, VP, Quality Operations**

More than 20 years of leadership experience in pharmaceutical quality operations and assurance in Canada and internationally

**Martin Poirier, MSc, VP CRO**

25 years of experience in biotech contract research organizations. Experience in scaling up businesses and growing operations, leading multi-disciplinary research team in drug discovery and development

**Holly Bilton, PhD, Associate Director, Business Development**

More than 8 years of experience in radiopharmaceutical development including early-stage discovery, development, and clinical programs

# Value Creation

## What We Have Done

### Company and Value Creation

2008



2011



2013



2016



2022



2025



**CanProbe created as a joint venture to manufacture research and clinical radiodiagnostics for Ontario**

**ARTMS created to commercialize solid target technology**

**Fusion Pharmaceuticals spun out to commercialize radiotherapeutics**

**AtomVie spun out to commercialize CRMO**

**Licensed F<sup>18</sup> FDG production to Isologic Radiopharm**

**Co-licensed radiotherapeutic PNT2003 to POINT Biopharma**

**Licensed radiodiagnostic F<sup>18</sup> PSMA-1007 from ABX for Canadian market**

**Seed-funded the microfluidics company, RadioSyn**

# Canadian Radiodiagnostic Leadership

## Where we came from

National leadership

**Leading radiopharmaceutical  
research, development, and  
commercialization since 2008**

---

**Registered [ $^{18}\text{F}$ ]-FDG and [ $^{18}\text{F}$ ]-  
NaF in Canada**

---

**Licensed [ $^{18}\text{F}$ ]-PSMA-1007 from  
ABX, completed Phase 3.  
Submitted Canadian market  
authorization, July 11, 2025**

---

**Funded and established  
diagnostic manufacturing  
network across Canada**



# Company Creation

## What we have done

Spin outs and licensing



## What we have done

CPDC is well capitalized  
to invest and drive  
future growth  
opportunities

# Value Creation

USD \$2.4 B

AstraZeneca 

Up to USD \$82 MM

 **Telix**

**Fusion**  
Pharmaceuticals Inc. 

**artms** 

 **AtomVie**  
Global Radiopharma

**POINT**  
BIOPHARMA

CAD \$90 MM

**AVEGO**

PNT2003

License:

USD \$1.4 B:

 **LANTHEUS**  
*Lilly*



## What's Next

Research, development,  
and clinical programs

Advancing  
radiopharmaceuticals  
discovery & development  
across Canada

# CPDC Exciting Projects:

## Translational research projects:

1 Therapeutic and 1 diagnostic program for oncology applications

## PSMA PET Phase 3 clinical trial:

Enrolled 100 Canadian prostate cancer patients for [F-18]-PSMA-1007 trial which closed in 2024

Health Canada NDS submitted July 11, 2025

## AI database for standardized quantitative and accurate image reporting:

In development for [<sup>18</sup>F]-PSMA-1007, designed to enable use with additional diagnostics

## Radiopharma production equipment investment:

Seed investment in new manufacturing device

## Radiopharma Contract Research Organization:


Launched a preclinical radiopharmaceutical CRO in October 2025



## Early Support

CRO offering early-stage,  
discovery and preclinical  
testing services

## CPDC CRO



## Early Support

CRO offering early-stage, discovery and preclinical testing services

## CPDC CRO

### Consulting and Advisory (an extension to what CPDC already offers)

- Advisory services for drug discovery, lead optimization and designing preclinical studies by CPDC team
- Providing guidance to our clients on quality, GMP and regulatory
- Navigating the drug development, filing requirements, approval process

### Laboratory testing

- In vitro and in vivo studies to help your testing needs
- Lead optimization, safety and ADME screening
- Covering from early-stage research all the way to IND-enabling studies

### Project management

- Ensuring timely completion and delivery of projects and studies for drug development
- Efficient use of time and resources

### Reporting

- Report writing/medical writing services by CPDC

## Our legacy with collaborators

Broad network to supply  
radiopharmaceuticals

# CPDC's Collaborators Include



**Dynamic, national  
community**

**Co-led by CPDC and  
TRIUMF Innovations**

# The Canadian Medical Isotope Ecosystem



\$80M initiative backed by \$35M from the Canada's Strategic Innovation Fund to position Canada as a global leader in medical isotope innovation



Accelerating research  
and development  
investment



Promoting cross-country  
collaboration



Nurturing talent

**Canadian Medical Isotope Development Fund (CMIEDF)**

**\$5MM to fund next generation medical isotope innovations**

# Major CMIE Programs and Projects

**Establishing domestic supply of Ac-225**

**Economic reconciliation with indigenous groups**

**Increasing supply of Lu-177**

**Increasing supply of I-125**

**Expanding research capacity at McMaster's research reactor**

**Providing advisory services to support scaling of radiopharmaceuticals**

**Advancing radiopharmaceuticals to clinical trials**



Canadian Nuclear  
Laboratories

Laboratoires Nucléaires  
Canadiens



**BrucePower™**  
Innovation at work




McMaster  
University 



Nuclear Operations  
& Facilities



# CMIE Development Fund



Offers financial support to innovators, developers, and academic institutions in Canada, specifically in the field of radiopharmaceutical and medical isotope technologies.

## Goals:

- Expedite the progress of early-stage programs
- Create a continuous pipeline for development and commercialization of medical isotope technologies



Join our Community to learn more (it's free!)

**Third Call for Proposals Currently Being Evaluated!**

# Development Fund Awardees:



**PROMATION**



**ACT225 BioTx**



**Synergy Oncology**



UNIVERSITY OF OTTAWA  
HEART INSTITUTE  
INSTITUT DE CARDIOLOGIE  
DE L'UNIVERSITÉ D'OTTAWA



Innovation, Science and  
Economic Development Canada

Innovation, Sciences et  
Développement économique Canada





Centre for Probe Development  
and Commercialization


*A Commercial Catalyst for the  
Greater Hamilton Area*





# Hamilton's Medical Isotope Ecosystem

1. **McMaster University  
Research Reactor**
2. **CPDC**
3. **Fusion  
Pharmaceuticals**
4. **AtomVie Global  
Radipharma**
5. **South West Exposures  
(specialized shielding)**



# Hamilton's Current Leadership Position



## Source of Medical Isotopes

MNR's has the capacity to produce several medical isotopes such as Lu-177, I-125, Ho-166, and others.



## Robust Clinical & Commercial Manufacturing

AtomVie is poised to be a global CDMO for the manufacturing and distribution of radiopharmaceuticals. **However, redundancy in the supply chain is needed.**



## Clinical Stage Drug Development

Fusion Pharmaceuticals is advancing multiple drugs through clinical trials, including therapeutics for prostate cancer and other solid tumors. **Additional diagnostics and therapeutics in the Canadian market are still needed.**



## Preclinical Drug Development

Researchers at McMaster are working on the development of next-generation radiopharmaceuticals for imaging and treatment of many diseases.



## Funding for Preclinical Development

Many start up companies and academics are looking for sources of funding to complete pivotal preclinical experiments to advance their programs to the clinic.



## Radiopharmaceutical Development CRO

Canadian companies and researchers struggle to find a CRO that conducts preclinical studies using radioisotopes.

# What Hamilton (and Canada) Needs – Building on What We Have



## Source of Medical Isotopes

MNR's has the capacity to produce several medical isotopes such as Lu-177, I-125, Ho-166, and others.



## Robust Clinical & Commercial Manufacturing

AtomVie is poised to be a global CDMO for the manufacturing and distribution of radiopharmaceuticals.

**CPDC is ensuring redundancy in GMP manufacturing by helping establish GMP production sites across Canada.**



## Clinical Stage Drug Development

Fusion Pharmaceuticals is advancing multiple drugs through clinical trials, including therapeutics for prostate cancer and other solid tumors.

**CPDC has recently completed a Phase 3 trial for a prostate cancer diagnostic. Health Canada approval is estimated in 2026.**



## Preclinical Drug Development

Researchers at McMaster are working on the development of next-generation radiopharmaceuticals for imaging and treatment of many diseases.



## Funding for Preclinical Development

Many start up companies and academics are looking for sources of funding to complete pivotal preclinical experiments to advance their programs to the clinic.

**The CMIE Development Fund provides funding and consulting to help accelerate Canadian medical isotope programs toward commercialization**



## Radiopharmaceutical Development CRO

Canadian companies and researchers struggle to find a CRO that conducts preclinical studies using radioisotopes.

**CPDC is partnering to establish a Canadian radiopharmaceutical CRO in 2025.**